Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, β-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap.

冠状动脉旁路移植术 (CABG) 手术后的二级预防对于减缓天然和移植血管中动脉粥样硬化的进展至关重要。阿司匹林和他汀类药物仍然是所有没有明显禁忌症的患者的主要药物。氯吡格雷双重抗血小板治疗的证据不太令人信服，但有希望使用更新的抗血小板药物，如替格瑞洛。同时，β-受体阻滞剂和血管紧张素转换酶抑制剂可能只对特定亚组有益。CABG 后患者似乎对一般心血管患者有不同的药物需求，反应也不同。在这篇综述中，我们介绍了最近指南提出的药物治疗方案及其使用背后的证据。评估这些建议背后的证据，我们发现，在某些领域，对针对特定人群的有力证据的需求未得到满足。我们希望未来的研究能够解决这一差距。